Sepsis remains a major cause of morbidity and mortality worldwide. The systemic release of the nuclear protein HMGB1 is a late event in endotoxin-related lethality in mice. The platinating chemotherapeutic Cis induces DNA lesions that sequester HMGB1 within the nucleus of cells. We sought to determine if low, nontoxic doses of Cis could be an effective strategy in ameliorating sepsis-related mortality in a mouse model of CLP. In vitro studies with Cis prevented the LPS-induced release of HMGB1 from RAW264.7 cells, limited MAPK signaling, but had no effect on NF-B activation or cytokine production. Low, nontoxic doses of Cis decreased mortality following CLP, whether delivered before or after puncture. Protection was associated with a decrease in the systemic release of HMGB1 and protection from end organ injury and in particular, less acute lung injury. Tissue-specific iNOS expression was markedly reduced. Low, nontoxic doses of Cis sequester HMGB1 effectively inside of the nucleus of LPS-stimulated immune cells and prevent its release in response to CLP. Platinating agents in general and Cis specifically may be a novel approach to the treatment of sepsis.
Introduction
Despite advances in critical care management and antibiotic therapies, sepsis remains a leading cause of death in the United States [1] . The pathogenesis of sepsis is characterized by inflammatory and immune responses that lead to downstream tissue damage, organ failure, and ultimately death. Unfortunately, clinical trials using therapeutic strategies that target proinflammatory mediators such as TNF-␣ and IL-1␤ have failed to improve sepsis-related survival [2] , possibly partly as a result of their early and transient kinetics.
In the late 1990s, the nuclear protein HMGB1 was identified as a late mediator of endotoxin and sepsis-related lethality in mice [3, 4] . Serum HMGB1 levels increase 8 h following administration of LPS and remain elevated for up to 32 h. Furthermore, delayed administration of neutralizing antibodies directed against HMGB1 attenuated lethality in this model. Elevated HMGB1 levels have also been documented in inflammatory conditions in patients [3, [5] [6] [7] . HMGB1 has thus become the focus of intense scrutiny and interest as a possible novel target in the treatment of sepsis. In addition to blocking its effects once released (such as with neutralizing antibodies), another rational strategy for targeting HMGB1 in the treatment of sepsis is to prevent its release. Accordingly, a number of agents have been identified, which block HMGB1 release, including nicotinic cholinergic agonists [8] , sterol lysophos-phatidylcholine [9] , ethyl pyruvate [4] , nafamostat mesilate [10] , ethacynic acid [11] , gold sodium thiomalate [12] , and ghrelin [13] .
Cis is a member of the platinating group of chemotherapeutic agents [14] and has been in clinical use for over 30 years. The therapeutic applications of Cis include the curative treatment of testicular cancer as well as the treatment of patients with most other epithelial malignancies, including cervical, breast, ovarian, head and neck, nonsmall cell lung cancers, and relapsing lymphomas [15] . Mechanistically, Cis forms DNA lesions including inter-and intrastrand cross-links [16] . Interestingly, Cis-induced DNA lesions cause conformational changes in the DNA double helix to which (HMGB1 included) they are able to bind quite stably [17] .
The aim of this study was to determine if Cis could serve as a novel therapeutic agent in the treatment of sepsis as a result of its ability to sequester HMGB1 within the nucleus of cells, preventing its egress and participation in driving recruitment of inflammatory cells. We found that in using in vitro studies with RAW264.7 macro-phages, nontoxic concentrations of Cis can inhibit the LPS-induced nucleocytoplasmic shuttling of HMGB1 as well as its release. Furthermore, administration of Cis at low, nontoxic doses attenuates end organ injury and lethality in a mouse model of polymicrobial sepsis induced by CLP through its ability to prevent the systemic release of HMGB1.
MATERIALS AND METHODS

Materials
rHMGB1 was purchased from R&D Systems (Minneapolis, MN, USA). LPS (Escherichia coli, serotype O55:B5) and Cis were purchased from Sigma-Aldrich (St. Louis, MO, USA), as were all other reagents used unless specified otherwise.
Animals
Male C57BL/6 mice (8-12 weeks old) were purchased from the Jackson Laboratory (Bar Harbor, ME, USA). All animals were maintained in a laminar-flow-specific, pathogen-free atmosphere at the University of Pittsburgh (PA, USA). The Animal Care and Use Committee of the University of Pittsburgh approved animal protocols, and the experiments were performed in adherence to NIH Guidelines for the Use of Laboratory Animals (Bethesda, MD, USA).
CLP
The CLP protocol was initiated with the abdominal wall clipped of hair and cleansed with betadine. Under ketamine (33 mg/kg i.p.) and xylazine (3.3 mg/kg i.p) anesthesia, a midline laparotomy was performed. The cecum was identified, and the distal 5 mm was ligated with a 4-0 silk suture and subsequently punctured once with a 22-gauge needle. Feces (1 mm) was extruded, and the cecum was returned to its i.p. location, after which time, the laparotomy incision was closed in two layers with a running suture of 5-0 nylon. A 0.03-cc/g bolus of NSS was administered s.c. immediately following closure of the laparotomy. This protocol results in 60 -70% mortality after 48 h. In experiments in which endpoints were examined at predetermined time-points, mice were anesthetized at the end of the observation period with inhaled isofluorane and killed via exsanguination.
In vivo experimental design
Male C57BL/6 mice were administered i.p. injections of Cis (0.1 or 1 mg/ kg) or NSS 1 h after the onset of CLP. In some experiments, mice were administered NSS or rHMGB1 (2 g/mouse) additionally, 16 h after the onset of the CLP protocol. Sham animals underwent anesthesia, laparotomy, and exposure of the cecum without ligation or puncture. In some experiments, mice were killed at predetermined time-points (16 -24 h) after CLP, and serum and tissue samples were harvested. In other experiments, 96 h survival rates were assessed.
Cell culture and treatment
Murine monocyte/macrophage-like cells (RAW 264.7, American Type Culture Collection, Manassas, VA, USA; 10 6 cells) were cultured in DMEM (BioWhittaker, Walkersville, MD, USA), supplemented with 10% FCS (Sigma-Aldrich), 50 U/ml penicillin, and 50 g/ml streptomycin (Cellgro/ Mediatech, Manassas, VA, USA) in 6 cm culture plates. LPS stimulations were carried out at the concentrations and for the duration of time, as indicated in the text. Varying doses of Cis (1-20 M) were added to the cell cultures 16 h prior to further stimulations as indicated.
TUNEL staining
To confirm apoptosis in Cis-treated RAW264.7 murine macrophage cells, TUNEL staining was performed. Cells were cultured in six-well plates with coverslips overnight and then treated with escalating concentrations of Cis for 20 h. Cells were washed with PBS and fixed in 4% paraformaldehyde for 20 min. Then, cells were permeabilized with 0.2% Triton X-100/PBS for 5 min, pretreated with equilibration buffer for 10 min, and then incubated in terminal-transferase reaction solution containing Nucleotide Mix and TdT enzyme (Clontech, Palo Alto, CA, USA) at 37°C for 60 min. Samples were protected from light, and the reaction was stopped by 2ϫ SSC and then washed and incubated with DAPI and Texas Red-X phalloidin (Invitrogen, Carlsbad, CA, USA) at room temperature for 20 min in the dark. Cells were then washed and analyzed using an Olympus Fluoview 1000 confocal microscope (Olympus, Center Valley, PA, USA).
Isolation of nuclear and cytoplasmic proteins
Frozen liver tissue was homogenized within 24 h of collection. Cells from in vitro experiments were scraped into ice-cold PBS. Samples were pelleted by microcentrifugation at 3000 g for 5 min. These pellets were then suspended in buffer containing 10 mM Tris, pH 7.5, 1.5 mM MgCl 2 , 10 mM KCl, and 0.1% Triton X-100 and allowed to lyse for 45 min. Nuclei were recovered by microcentrifugation at 1500 g for 5 min. The supernatant that contained cytoplasmic and membrane proteins was collected and stored at -80°C for Western blot analysis. Nuclear proteins were extracted at 4°C by resuspending the nuclei pellet gently in buffer containing 20 mM Tris, pH 7.5, 20% glycerol, 1.5 mM MgCl 2 , 420 mM NaCl, 0.2 mM EDTA, and 0.1% Triton X-100, followed by 1 h incubation at 4°C with occasional vortexing. After microcentrifugation at 10 4 g for 15 min at 4°C, the supernatant that contained nuclear proteins was collected. Protein concentration was quantitated with bicinchoninic acid protein assay reagent (Pierce Chemical Co., Rockford, IL, USA).
Organ damage assessment
To assess hepatic function and cellular injury, sALT levels were measured using the Opera Clinical Chemistry System (Bayer Co.) and are reported as international units/L. To assess kidney function, serum blood urea nitrogen and creatinine levels were measured using the same system and are reported as mg/dL.
Histopathology
Formalin-fixed lung samples were embedded in paraffin and cut to 6-mthick sections. Tissues were stained with H&E, and slides were assessed for inflammation and tissue damage.
Immunohistochemistry
Thick tissue sections 4 -6 were deparaffinized in xylene using three changes for 5 min each. Sections were then hydrated gradually through graded alcohols and then washed in deionized H 2 O for 1 min with stirring. Sections were then incubated for 30 min in 0.05% saponin in deionized H 2 O at room temperature and washed three times in PBS and then incubated for 10 min in 0.1-1% hydrogen peroxide in deionized H 2 O to quench endogenous peroxidase activity. Next, three washes in PBS ϫ 5 min each were performed, and then specimens were incubated for 1 h in 1.5% normal blocking serum and then with rabbit anti-HMGB1 (1:100) overnight at 4°C. Washes (3ϫ5 min) with PBS were performed, followed by incubation for 30 min with biotin-conjugated goat anti-rabbit secondary antibody. Then, 3 ϫ 5 min washes with PBS, followed by incubation for 30 min with avidin biotin enzyme reagent, were performed, followed by three more 5 min washes with PBS. Then, sections were incubated in peroxidase substrate for 3 min, washed in deionized H 2 O for 5 min, counter-stained in hematoxylin for 5 s, washed immediately with several changes of deionized H 2 O, followed by dehydration through alcohols and xylenes, and then covered with a glass coverslip and observed by light microscopy.
Immunofluorescent staining
RAW264.7 cells were treated as described in the text and then washed three times with PBS prior to being fixed in 2% paraformaldehyde and permeabilized in 0.1% Triton X-100 (Sigma-Aldrich). Next, cells were rehydrated with three washes of PBS, washed five times with 0.5% BSA, and blocked with 2% BSA for 45 min. After blocking, cells were washed five times with 0.2% BSA before being incubated with primary antibody (anti-HMGB1; AbCam, Cambridge, MA, USA), diluted 1:100 for 60 min, after which time, they were washed again five times with 0.2% BSA, incubated with Alexa 488-conjugated secondary (Invitrogen), diluted 1:500 for 60 min, and then washed again five times in 0.2% BSA. Confocal analysis was performed on an Olympus Fluoview 1000 confocal microscope.
SDS/PAGE and Western blotting
Western blot analysis for HMGB1 and iNOS were performed as described previously [18] . Primary polyclonal rabbit antibodies to HMGB1 (diluted 1:1000; AbCam), iNOS (1:1000; B&D Biosystems), and P65 (1:1000; Santa Cruz Biotechnology, Santa Cruz, CA, USA) were used for Western blot. Membranes were developed with the Super Signal West Pico chemiluminescent kit (Pierce Chemical Co.) and exposed to film. Densitometry was performed by the NIH Image Program to quantify OD.
EMSA
EMSA was performed using oligonucleotides as described previously [19] . Excess unlabeled oligonucleotide and excess unlabeled mutant oligonucleotide were added in some reaction mixtures to ensure specificity of binding.
Statistical analysis
Fisher exact test was used to compare categorical variables between those animals that received Cis and those control animals that did not. Survival was estimated using Kaplan-Meier methods.
RESULTS
Cis administration in vivo attenuates CLP-induced lethality
To determine the in vivo toxicity of Cis, escalating, logarithmic doses of Cis ranging from 0.1 to 10 mg/kg were administered to male C57BL/6 mice. No evidence of hepato -or nephrotoxicity was observed over this dose range of Cis 72 h following administration (data not shown). To determine the effect of Cis on CLPinduced lethality, C57BL/6 mice were given i.p. injections of Cis (0.1 mg/kg or 1 mg/kg) or NSS 1 h after the onset of CLP. Ninety-six hour survival rates were improved in the low-dose (0.1 mg/kg) Cis compared with NSS-treated mice (PϽ0.001). This protective effect was not seen with the administration of higher doses (1 mg/kg) of Cis (Fig. 1A) .
Cis administration prevents CLP-induced systemic HMGB1 release
To determine if the protective effect of low-dose (0.1 mg/kg) Cis administration was associated with an inhibition of the systemic release of HMGB1, Western blot analysis was performed on serum samples obtained from mice 24 h following the onset of CLP. Sham-operated mice had undetectable systemic levels of HMGB1, and NSS-injected mice had HMGB1 present in their serum 24 h following CLP. In contrast, Cis-injected mice had undetectable levels of HMGB1 similar to that seen in sham-operated animals. These differences proved to be statistically significant when quantitated by band densitometry (Fig.  1B) . Furthermore, to determine if Cis affects the systemic production of other cytokines known to contribute to sepsis-induced inflammation, ELISA was performed for IL-6 and TNF-␣ on serum obtained from mice 16 h following the onset of CLP. Although there was a trend toward decreased production of IL-6 and TNF-␣, no statistically significant difference was observed in the systemic levels of these cytokines in the Cis compared with the NSS-treated mice (Fig. 1C) . These results suggest that Cis attenuates CLP-induced lethality through its ability to prevent the systemic release of HMGB1.
Cis administration prevents HMGB1-mediated end organ injury following CLP
End organ damage is the primary cause of sepsis-related death, and acute lung injury is a major manifestation of such. HMGB1 release contributes to the development of acute lung injury in rodent models of sepsis [20] , in part, as a result of its ability to induce the expression of the iNOS gene [21] . To determine if the in vivo administration of low doses (0.1 mg/kg) of Cis prevented CLP-induced acute lung injury, H&E staining was performed on formalin-fixed sections of lungs obtained from sham-operated mice as well as those that had undergone CLP followed by the administration of Cis (0.1 mg/kg) or NSS. In NSS-injected mice, CLP induced the deposition of hyaline as well as the infiltration of inflammatory cells. Cis administration abrogated this response almost completely (Fig. 2A) . Immunohistochemistry revealed that HMGB1 staining was increased in the lungs of NSS compared with Cis-treated mice following CLP (Fig. 2B) . Furthermore, Western blot analysis revealed that CLP resulted in the expression of iNOS in the lungs of NSS-treated mice. This process was inhibited by Cis administration. Band denisometry confirmed that the decreased pulmonary expression of iNOS was statistically significant (Fig. 2C) . These results suggest that Cis prevents HMGB1-mediated end organ damage following CLP.
rHMGB1 administration restores CLP-induced mortality in Cis-treated mice
To explore the central importance of HMGB1 further in the protection from sepsis-induced lethality that was observed in low-dose (0.1 mg/kg) Cis compared with NSS-treated mice, additional experiments were performed, in which mice were treated with Cis and then given i.p. injections of NSS or rHMGB1 (2 g/mouse) 16 h after the onset of the CLP protocol. rHMGB1 administration to normal, untreated mice did not cause any mortality in the absence of CLP. This was likely a result of the low dose of rHMGB1 that was used; however, when administered to mice that had undergone CLP, it did restore CLP-induced mortality in Cis-injected mice (Fig. 3) . These results indicate that the administration of even small amounts of rHMGB1 to Cis-treated mice that had undergone CLP was sufficient to restore mortality and substantiate further that the protective effects of Cis in this CLP model are mediated primarily through its ability to prevent the systemic release of HMGB1.
Cis prevents LPS-induced nucleocytoplasmic shuttling of HMGB1 in vitro in RAW264.7 cells
As Cis decreased the CLP-induced release of HMGB1 in vivo, in vitro methods were used to determine if it can also retain HMGB1 inside of the nucleus of LPS-stimulated RAW264.7 cells. When the concentrations of Cis approached 20 M cell viability, as assessed by MTT assay (Fig. 4A) and TUNEL staining (Fig. 4B) , they began to be altered significantly. Western blot analysis on extracts from RAW cells that had been treated 
Permanent blocks of lung tissue obtained from NSS or
Cis-injected mice 24 h after the onset of the CLP protocol were sectioned and (A) stained with H&E, or (B) immunohistochemistry for HMGB1 was performed. (C) Western blot analysis for iNOS was performed on whole cell lysates from lung tissue of NSS or Cis-treated mice that had undergone CLP. Sham-operated mice underwent anesthesia and laparotomy only. iNOS Western blot analysis was quantitated by densitometry; means Ϯ sem OD of individual iNOS immunoblots. *, P Ͻ 0.05, versus CLP group; n ϭ 3. , and 48 h survival was observed. In another group, rHMGB1, at a dose of 2 g/mouse, was given 16 h after the onset of CLP to mice that had been treated with Cis, and 48 h survival was observed (dotted bar). In the final group, rHMGB1 was given at a dose of 2 g/mouse to naïve mice, and 48 h survival was observed (hatched bar); n ϭ 8/group. *, P Ͻ 0.05, compared with CLP group; #, P Ͻ 0.05, compared with CLP ϩ Cis group.
with escalating concentrations of Cis ranging from 1 to 10 M revealed that Cis induced the retention of HMGB1 inside of the nucleus (Fig. 5A) and prevented the cytosolic accumulation of HMGB1 (Fig. 5B ) in the setting of LPS stimulation. This effect occurred in a concentration-dependent manner. Furthermore, immunofluorescent staining confirmed that the LPS-induced nucleocyoplasmic shuttling of HMGB1 is prevented by Cis (Fig. 5C ). These in vitro findings correlate with the in vivo findings in which Cis was able to prevent the sepsisinduced release of HMGB1.
Cis modulates LPS-induced MAPK activation in vitro
MAPK signaling has been implicated in the pathogenesis of end organ injury in sepsis [22] [23] [24] . Specifically, P38 MAPK activation has been shown to contribute to pulmonary end organ damage and cardiomyocyte dysfunction. Cis is known to be able to modulate a number of intracellular stress-signaling pathways including the MAPK pathways [25, 26] . Therefore, RAW264.7 cells were stimulated with LPS in the presence of escalating concentrations of Cis, and MAPK activation was measured by Western blot analysis (Fig. 6, A-C) . Cis up-regulated phosphorylated ERK expression in response to LPS stimulation but suppressed phosphorylation of P38 and JNK. These results indicate that Cis can alter LPSinduced MAPK activation in macrophages.
Cis does not affect LPS-induced NF-␤ activation or the production of inflammatory mediators in RAW264.7 cells
NF-B activation is well described as playing an important role in the inflammatory response during sepsis [27, 28] . Cis affects NF-B activation in a number of cell types [29, 30] . Therefore, to determine the effect of Cis on LPS-induced NF-B activation in RAW264.7 cells, EMSA was performed. No difference was observed in LPS-induced NF-B activation in untreated versus Cis-treated cells over the concentration range that was examined (0 -20 M; Fig. 7A) . Furthermore, the LPS-induced nuclear accumulation of the P65 subunit of NF-〉 was unaffected by Cis (Fig. 7B) . Additionally, Cis can induce the pro- Western blot analysis for HMGB1 was performed on (A) nuclear and (B) cytoplasmic extracts of RAW264.7 cells that were treated with LPS (100 ng/mL) for 8 h in the presence or absence of escalating doses of Cis. Histone and actin blots represent loading controls. Densitometry analysis was performed to quantitate the differences in nuclear and cytoplasmic HMGB1 levels; means Ϯ sem OD of individual HMGB1 immunoblots; n ϭ 3. *, P Ͻ 0.05, versus LPS alone (100 ng/mL). (C) Immunofluorescent staining for HMGB1 was performed on RAW264.7 cells stimulated with LPS (100 ng/ mL) for 8 h. HMGB1 stains green, and nucleus (DAPI) stains blue (magnitude ϫ630). Results are representative of three separate, independent experiments. duction of iNOS and inflammatory cytokines such as IL-1␤, TNF-␣, and IFN-␥ in macrophages [31] [32] [33] . Therefore, to determine if low, nontoxic concentrations of Cis affected LPSinduced cytokine expression or iNOS production in RAW cells, ELISA and Western blot analysis were performed. No significant difference in these endpoints was observed over the tested concentration range of Cis (Fig. 7, C and D) .
DISCUSSION
Sepsis remains a major cause of morbidity and mortality worldwide, accounting for approximately $17 billion in healthcare costs annually [34] . Despite this fact, few therapeutic interventions have demonstrated clinical efficacy in impacting the outcomes of patients with established sepsis. The purpose of the present study is to determine the ability of low, nontoxic doses of Cis to attenuate mortality in a mouse model of polymicrobial sepsis induced by CLP. In vivo, a beneficial effect of CLP-induced mortality was seen with low-dose (0.1 mg/kg) Cis administration. The ability of low-dose Cis to prevent mortality in this model appears to be related, in part, to its ability to sequester HMGB1 inside of the nucleus of macrophages. Additionally, a decrease in CLP-induced end organ injury was observed with the administration of low-dose Cis, and less evidence of acute lung injury was apparent in Cis-treated mice. This correlated with decreased tissue expression of iNOS, which has been shown to be an important mediator of acute lung injury that is partly expressed in response to extracellular HMGB1 [21] . No difference in CLP-induced mortality was observed with higher doses (1 mg/kg) of Cis. This may be a result of the fact that higher doses of Cis can induce the expression of inflammatory cytokines including TNF-␣, IL-1␤, and IFN-␥, all of which can amplify the inflammatory response following sepsis [35] . Furthermore, in vitro studies demonstrate that higher doses of Cis induce macrophage apoptosis, which may also contribute to the relatively narrow therapeutic window that was observed in vivo. Therefore, the beneficial ability of Cis to prevent the CLP-induced release of HMGB1 appears to exist at low doses, and at higher doses, the toxic effects begin to predominate. The in vivo findings were corroborated with in vitro studies in which low, nontoxic concentrations of Cis were found to inhibit LPS-induced HMGB1 release from RAW264.7 cells.
HMGB1 is a nuclear protein that is expressed in all eukaryotic cells. It was identified originally in the early 1970s in an effort to better characterize specific regulators of gene transcription. It binds transiently and without sequence specificity to the minor groove of DNA and in so doing, has homeostatic functions that include the regulation of gene transcription as well as DNA organization [36] . As its identification as a late mediator of endotoxin-related lethality in mice in the late 1990s [3] , HMGB1 has been the focus of considerable interest as a possible novel target in treating septic patients. Of particular interest is the late kinetics of systemic HMGB1 expression as well as its role in the development and progression of end organ injury. Rational strategies in targeting HMGB1 in the treatment of sepsis include inhibiting its release as well as blocking its effects once released. In this regard, experiments with polyclonal, neutralizing antibodies directed against HMGB1 in rodent models of sepsis have resulted in improved survival [3] . Furthermore, similar experiments using HMGB1-neutralizing antibodies have proven to be beneficial in preventing endotoxin-induced acute lung injury [37] . Additionally, a number of studies have shown that a variety of agents are capable of preventing the systemic release of HMGB1 during sepsis, including cholinergic agonists, ethyl pyruvate, gold sodium thiomalate [12] , and most recently, ghrelin [4, 8, 13] . Other members of the platinating group of chemotherapeutic agents, such as carboplatin and oxaliplatin, share the ability of Cis to form DNA lesions, which sequester HMGB1 effectively inside of the nucleus of cells. In fact, oxaliplatin has been shown recently to be able to inhibit the development and severity of collagen-induced arthritis partially in a mouse model [38] . We chose to examine the effects of Cis as opposed to oxaliplatin as a result of the fact that 90% of the Cisinduced DNA adducts formed in vivo are believed to be of the 1,2-d(GpG) or 1,2-d(ApG) type that show the highest affinity for HMGB1. These Cis-induced DNA lesions widen and flatten the minor groove opposite of the lesion and greatly facilitate HMG domain protein recognition. Conversely, the molecular geometry of oxaliplatin-induced DNA adducts is such that HMGB1 binds much less avidly [39] .
In addition to their ability to bind HMGB1 inside of the nucleus of cells, Cis-induced DNA adducts have been shown to be able to alter intracellular stress-signaling pathways such as the MAPK and NF-B pathways [25] . This led us to examine the effects of Cis on these pathways in LPS-stimulated RAW264.7 cells. We found that Cis modulates LPS-induced MAPK signaling. P38 and JNK activation was inhibited by Cis. Previous reports have demonstrated that HMGB1 release from inflammatory cells may be mediated via a MAPK-dependent pathway [40] ; therefore, the ability of Cis to modulate these pathways may contribute further to its ability to prevent HMGB1 release. Furthermore, P38 and JNK activation has been shown to contribute to sepsis-induced end organ injury [23, 24, 41] . Conversely, we found that Cis enhances ERK activation in RAW cells at baseline as well as in response to LPS stimulation. ERK activation has been shown to prevent leukocyte apoptosis, which is a hallmark of sepsis and contributes to disease mortality [42] . In addition to its ability to affect MAPK signaling, we had interest in the ability of Cis to potentially alter NF-B activation and inflammatory cytokine production. However, we found that Cis at the concentrations that we studied had no effect on LPS-induced NF-B activation or proinflammatory cytokine and iNOS production. The apparent conflicting findings, that Cis was able to prevent the expression of iNOS in the lungs of septic mice (Fig. 2C ) but did not prevent its LPS-induced expression in RAW cells, may be reconciled by the fact that iNOS production in the setting of sepsis-induced acute lung injury is mediated by systemic HMGB1 release [21] , which was decreased by Cis administration in vivo. However, LPS-stimulated iNOS production in RAW cells proceeds through the activation of NF-B, which was unaffected by Cis in vitro [43] .
In summary, we describe a novel application of the well-studied platinum chemotherapeutic agent, Cis, in attenuating mortality in a mouse model of polymicrobial sepsis induced by CLP, the beneficial effects of which appear to be mediated potentially by its ability to prevent the release of HMGB1 from immune cells. The use of platinating agents in the treatment of sepsis may, therefore, represent a novel approach to the management of a clinical problem whose solution at present remains elusive.
